Recently, we have shown the power of neuroinflammation, i.e., the role of IL-1β and its downstream signaling cascade, in glioblastoma pathogenesis, demonstrating targeting IL-1β and its signaling cascade using an IL-1 Receptor Antagonist as a promising therapy [30]. The gene discussed is IL1B; the disease is glioblastoma.